Park, Kaapjoo team published research in Bioorganic & Medicinal Chemistry in 2014 | 38256-93-8

38256-93-8, 2-Methoxy-N-methylethanamine is a useful research compound. Its molecular formula is C4H11NO and its molecular weight is 89.14 g/mol. The purity is usually 95%.
2-Methoxy-N-methylethanamine is a drug that binds to the cannabinoid receptor CB1. It has been shown to be effective in the treatment of cardiac arrhythmia and may also be used as an anti-inflammatory drug. 2MEMEA has been shown to have pharmacokinetic properties that are different from those of other amines, which may be due to its ability to form hydrogen bonds with water molecules. 2MEMEA also has diversified effects on some types of cancer cells, including hyperproliferative and amine-dependent cancers., Reference of 38256-93-8

Ethers are a class of organic compounds that contain an ether group—an oxygen atom connected to two alkyl or aryl groups. 38256-93-8, formula is C4H11NO, Name is 2-Methoxy-N-methylethanamine.They have the general formula R–O–R′, where R and R′ represent the alkyl or aryl groups. Reference of 38256-93-8.

Park, Kaapjoo;Lee, Byoung Moon;Hyun, Kwan Hoon;Lee, Dong Hoon;Choi, Hyun Ho;Kim, Hyunmi;Chong, Wonee;Kim, Kyeong Bae;Nam, Su Youn research published 《 Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus》, the research content is summarized as follows. Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10 mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-Me pyridin-2-yl)-benzamide (19e) was identified as a potent glucokinase activator with assays demonstrating an EC50 of 315 nM and the induction of a 2.23 fold increase in glucose uptake. Compound 19e exhibited a glucose AUC reduction of 32% (50 mg/kg) in an OGTT study with C57BL/6J mice compared to 28% for metformin (300 mg/kg). Single treatment of the compound in C57BL/J6 and ob/ob mice elicited basal glucose lowering activity, while in a two-week repeated dose study with ob/ob mice, the compound significantly decreased blood glucose levels with no evidence of hypoglycemia risk. In addition, 19e exhibited favorable pharmacokinetic parameters in mice and rats and excellent safety margins in liver and testicular toxicity studies. Compound 19e was therefore selected as a development candidate for the potential treatment of type 2 diabetes.

38256-93-8, 2-Methoxy-N-methylethanamine is a useful research compound. Its molecular formula is C4H11NO and its molecular weight is 89.14 g/mol. The purity is usually 95%.
2-Methoxy-N-methylethanamine is a drug that binds to the cannabinoid receptor CB1. It has been shown to be effective in the treatment of cardiac arrhythmia and may also be used as an anti-inflammatory drug. 2MEMEA has been shown to have pharmacokinetic properties that are different from those of other amines, which may be due to its ability to form hydrogen bonds with water molecules. 2MEMEA also has diversified effects on some types of cancer cells, including hyperproliferative and amine-dependent cancers., Reference of 38256-93-8

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem